Tiziana Life Sciences LTD (TLSA) — SEC Filings

Overview

Tiziana Life Sciences LTD (TLSA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 16, 2026: Tiziana Life Sciences Ltd. filed a Form 6-K on April 16, 2026, reporting as a foreign issuer. The filing includes a press release dated April 16, 2026, and associated graphic files. The company's mailing and business address is in London, England.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 16 bullish, 1 bearish, 33 neutral. The dominant filing sentiment for Tiziana Life Sciences LTD is neutral.

Filing Type Overview

Tiziana Life Sciences LTD (TLSA) has filed 48 6-K, 1 20-F/A, 1 20-F with the SEC between Oct 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Tiziana Life Sciences Files 6-K Report — 6-K · Apr 16, 2026 Risk: low
  Tiziana Life Sciences Ltd. filed a Form 6-K on April 16, 2026, reporting as a foreign issuer. The filing includes a press release dated April 16, 2026, and asso
• 6-K Filing — 6-K · Apr 14, 2026
• Tiziana Life Sciences Files 6-K Report — 6-K · Apr 1, 2026 Risk: low
  Tiziana Life Sciences Ltd. filed a Form 6-K on April 1, 2026, reporting as a foreign issuer. The filing includes a press release dated April 1, 2026, and associ
• Tiziana Life Sciences Submits 7th Annual Safety Report to FDA — 6-K · Dec 29, 2025 Risk: low
  On December 29, 2025, Tiziana Life Sciences LTD announced the submission of its seventh annual Development Safety Update Report (DSUR) to the U.S. Food and Drug
• 6-K Filing — 6-K · Dec 19, 2025
• Tiziana Life Sciences Doses First Patient in Alzheimer's Trial — 6-K · Dec 17, 2025 Risk: medium
  On December 17, 2025, Tiziana Life Sciences LTD announced that the first patient has been dosed with intranasal foralumab in a Phase 2 clinical trial for early
• Tiziana Life Sciences Withdraws Public Offering — 6-K · Dec 15, 2025 Risk: medium
  Tiziana Life Sciences Ltd announced on December 15, 2025, the withdrawal of its proposed public offering of common shares. This decision was made due to prevail
• 6-K Filing — 6-K · Dec 12, 2025
• 6-K Filing — 6-K · Dec 2, 2025
• Tiziana Life Sciences' ALS Trial Joins MyMatch Program — 6-K · Nov 25, 2025 Risk: medium
  Tiziana Life Sciences Ltd announced on November 25, 2025, that its Phase 2 clinical trial for intranasal foralumab in ALS patients has been accepted into the AL
• Tiziana Life Sciences to Present at Jefferies London Healthcare Conference — 6-K · Nov 13, 2025 Risk: medium
  Tiziana Life Sciences Ltd announced on November 13, 2025, that its senior leadership team, including CEO Ivor Elrifi and COO/CFO Keeren Shah, will present at th
• Tiziana Life Sciences to Present at BIO-Europe 2025 — 6-K · Oct 29, 2025 Risk: low
  Tiziana Life Sciences Ltd announced on October 29, 2025, its participation as a presenting company at BIO-Europe 2025. This premier life sciences partnering con
• Tiziana Life Sciences Reports Interim Financials & Program Update — 6-K · Oct 3, 2025 Risk: medium
  Tiziana Life Sciences Ltd. filed a Form 6-K on October 3, 2025, reporting its interim financial results for the six months ended June 30, 2025. The filing also
• Tiziana Life Sciences Invited to J.P. Morgan Life Science Forum — 6-K · Sep 30, 2025 Risk: low
  Tiziana Life Sciences Ltd. announced on September 30, 2025, that it has been invited to the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2
• Tiziana Life Sciences Advances Anti-IL-6R Antibody TZLS-501 — 6-K · Sep 25, 2025 Risk: medium
  On September 25, 2025, Tiziana Life Sciences LTD announced it is advancing its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501. This move comes ami
• Tiziana Life Sciences to Present at ECTRIMS Congress — 6-K · Sep 24, 2025 Risk: low
  Tiziana Life Sciences LTD announced on September 24, 2025, that it will present a scientific poster at the 41st Congress of the European Committee for Treatment
• Tiziana Life Sciences Secures DoD Grant for Spinal Cord Injury Therapy — 6-K · Sep 15, 2025 Risk: medium
  On September 15, 2025, Tiziana Life Sciences Ltd announced it received a research grant from the U.S. Department of Defense (DoD) to study intranasal anti-CD3 t
• Tiziana Life Sciences CEO Buys Shares — 6-K · Sep 9, 2025 Risk: medium
  On September 9, 2025, Tiziana Life Sciences LTD announced that its CEO, Ivor Elrifi, purchased 193,848 shares of the company's common stock in the open market.
• Tiziana Life Sciences Chairman Buys Shares — 6-K · Sep 5, 2025 Risk: medium
  On September 5, 2025, Tiziana Life Sciences Ltd announced that its Executive Chairman and Founder, Gabriele Cerrone, purchased 25,000 common shares at $1.60 per
• Tiziana Life Sciences Doses First Patient in MSA Trial — 6-K · Aug 14, 2025 Risk: medium
  Tiziana Life Sciences Ltd. announced on August 14, 2025, that the first participant has been enrolled and dosed in its Phase 2a clinical trial. This trial, taki
• Tiziana Life Sciences FDA Approves IND for MSA Trial — 6-K · Aug 11, 2025 Risk: medium
  On August 11, 2025, Tiziana Life Sciences Ltd announced that the U.S. Food & Drug Administration (FDA) has approved the Investigational New Drug (IND) applicati
• Tiziana Life Sciences Reports Alzheimer's Treatment Findings — 6-K · Jul 21, 2025 Risk: medium
  On July 21, 2025, Tiziana Life Sciences Ltd announced compelling immunologic findings from treating a moderate Alzheimer's Disease patient with intranasal foral
• Tiziana Life Sciences CEO to Present Clinical Findings at Bio Convention — 6-K · Jun 13, 2025 Risk: medium
  Tiziana Life Sciences LTD announced on June 13, 2025, that CEO Ivor Elrifi will present recent clinical findings for the company's lead drug at the Bio Internat
• Tiziana Life Sciences Alzheimer's Nasal Spray Featured on NPR — 6-K · May 23, 2025 Risk: medium
  Tiziana Life Sciences Ltd announced on May 23, 2025, advancements in its Alzheimer's disease treatment using its novel nasal spray, Foralumab. This development
• Tiziana Life Sciences Study Shows Foralumab Dampens Microglial Activation — 6-K · May 15, 2025 Risk: medium
  Tiziana Life Sciences Ltd announced on May 15, 2025, the publication of a new study in the Journal of 'Clinical Nuclear Medicine'. The study demonstrates that i
• Tiziana Life Sciences Founder Buys Shares — 6-K · May 12, 2025 Risk: medium
  On May 12, 2025, Tiziana Life Sciences LTD announced that its Executive Chairman and Founder, Gabriele Cerrone, purchased 15,000 common shares at $1.55 per shar
• Tiziana Life Sciences Reports Alzheimer's Treatment Success — 6-K · May 9, 2025 Risk: medium
  On May 9, 2025, Tiziana Life Sciences LTD announced positive results from a PET scan. The scan showed a significant reduction in microglia activation, a marker
• Tiziana Life Sciences Files 20-F/A Amendment — 20-F/A · May 8, 2025 Risk: medium
  Tiziana Life Sciences Ltd filed an amendment (20-F/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on May 8, 2025, is
• Tiziana Life Sciences Files 2024 Annual Report — 20-F · May 6, 2025 Risk: medium
  Tiziana Life Sciences Ltd filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Delaware (D0) and headq
• Tiziana Life Sciences Starts Dosing at Fourth Site for MS Trial — 6-K · Apr 23, 2025 Risk: medium
  On April 23, 2025, Tiziana Life Sciences LTD announced that dosing has begun at the fourth clinical site for its Phase 2 trial. This trial is evaluating intrana
• Tiziana Life Sciences Doses Patients in SPMS Trial at Johns Hopkins — 6-K · Apr 2, 2025 Risk: medium
  Tiziana Life Sciences Ltd. announced on April 2, 2025, that dosing has begun at Johns Hopkins University (JHU) Autoimmunity Center of Excellence for its Phase 2
• Tiziana Life Sciences Doses New Patients in MS Trial — 6-K · Mar 25, 2025 Risk: medium
  On March 25, 2025, Tiziana Life Sciences LTD announced the dosing of new patients at Yale MS Center in their multicenter Phase 2 clinical trial. This trial is e
• Tiziana Life Sciences CEO to Speak at ROTH Conference — 6-K · Mar 17, 2025 Risk: low
  Tiziana Life Sciences LTD announced on March 17, 2025, that its CEO, Ivor Elrifi, will participate in a fireside chat and host investor meetings at the 37th Ann
• Tiziana Life Sciences Regains Nasdaq Listing Compliance — 6-K · Mar 14, 2025 Risk: low
  On March 4, 2025, Tiziana Life Sciences LTD received notification from Nasdaq that it has regained compliance with Nasdaq's minimum bid price listing requiremen
• Tiziana Life Sciences Files IND for ALS Phase 2 Trial — 6-K · Mar 4, 2025 Risk: medium
  On March 4, 2025, Tiziana Life Sciences LTD announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration
• Tiziana Life Sciences Study Shows Nasal Antibody Reduces Neuroinflammation — 6-K · Feb 27, 2025 Risk: medium
  Tiziana Life Sciences Ltd announced on February 27, 2025, the publication of a study in Nature Neuroscience. The study demonstrated that their anti-CD3 monoclon
• Tiziana Life Sciences' Foralumab Shows Promise for Long COVID — 6-K · Feb 25, 2025 Risk: medium
  Tiziana Life Sciences Ltd. announced on February 25, 2025, that its nasal anti-CD3 (foralumab) preclinical study is nearing completion. The company believes for
• Tiziana Life Sciences Partners with Renaissance for Nasal Drug Delivery — 6-K · Feb 21, 2025 Risk: low
  On February 21, 2025, Tiziana Life Sciences LTD announced a product development services agreement with Renaissance Lakewood LLC, a Contract Development and Man
• Tiziana Life Sciences Doses More MS Patients in Expanded Access Program — 6-K · Feb 18, 2025 Risk: medium
  On February 18, 2025, Tiziana Life Sciences LTD announced the dosing of four additional patients in its Intermediate Size Patient Population Expanded Access (IS
• Tiziana Life Sciences Drug Featured on News Channel — 6-K · Feb 11, 2025 Risk: medium
  On February 11, 2025, Tiziana Life Sciences LTD announced that its investigational drug, intranasal foralumab, was featured on a prominent news channel. The seg
• Tiziana Life Sciences Faces Nasdaq Delisting Warning — 6-K · Jan 31, 2025 Risk: medium
  On January 29, 2025, Tiziana Life Sciences Ltd received a notice from Nasdaq stating it is not in compliance with the $1.00 Minimum Bid Price Requirement for co
• Tiziana Life Sciences Reports SCI Study Results — 6-K · Jan 24, 2025 Risk: medium
  On January 23, 2025, Tiziana Life Sciences LTD announced positive results from studies utilizing a nasal anti-CD3 monoclonal antibody for treating traumatic spi
• Tiziana Life Sciences Discovers New MS Biomarkers — 6-K · Jan 22, 2025 Risk: medium
  On January 22, 2025, Tiziana Life Sciences LTD announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple scler
• Tiziana Life Sciences: Nasal Antibody Shows Prolonged Benefits — 6-K · Jan 10, 2025 Risk: medium
  On January 10, 2025, Tiziana Life Sciences LTD announced positive findings regarding its nasal anti-CD3 monoclonal antibody. The antibody has shown prolonged be
• Tiziana Life Sciences' Foralumab Highlighted in Nature Reviews Neurology — 6-K · Jan 8, 2025 Risk: medium
  On January 8, 2025, Tiziana Life Sciences LTD announced that a review article titled "Immune mechanisms and shared immune targets in neurodegenerative diseases"
• Tiziana Life Sciences Doses First Alzheimer's Patient — 6-K · Dec 17, 2024 Risk: medium
  On December 17, 2024, Tiziana Life Sciences LTD announced a significant milestone in its Alzheimer's disease clinical development program. The company successfu
• Tiziana Life Sciences Expands Phase 2 SPMS Trial — 6-K · Dec 4, 2024 Risk: medium
  On December 4, 2024, Tiziana Life Sciences LTD announced the expansion of its Phase 2 clinical trial for intranasal foralumab. This trial is evaluating the drug
• Tiziana Life Sciences Secures ALS Association Grant — 6-K · Nov 19, 2024 Risk: medium
  Tiziana Life Sciences LTD announced on November 19, 2024, that its grant application to the ALS Association has been approved for funding. This grant is part of
• Tiziana Life Sciences Prices $10M Direct Offering — 6-K · Nov 1, 2024 Risk: medium
  On October 30, 2024, Tiziana Life Sciences Ltd. entered into a securities purchase agreement with an institutional investor to sell 5,263,158 common shares. The
• Tiziana Life Sciences Reports Positive Anti-Inflammatory Results — 6-K · Oct 30, 2024 Risk: medium
  Tiziana Life Sciences Ltd announced on October 30, 2024, positive results for its anti-CD3 antibody, foralumab, when used in combination with semaglutide. This

Related Companies

NVO

Frequently Asked Questions